Tom 7, Nr 5 (2021)
Artykuł przeglądowy
Opublikowany online: 2021-11-25
Wyświetlenia strony
3033
Wyświetlenia/pobrania artykułu
225
Kliniczne prognostyczne i predykcyjne czynniki kwalifikacji do immunoterapii
Onkol Prakt Klin Edu 2021;7(5):301-306.
Streszczenie
Kwalifikacja chorych do immunoterapii opiera się na wskazaniach rejestracyjnych leków z uwzględnieniem zapisów programów lekowych. Obserwacje z codziennej praktyki pozwalają wskazać dodatkowe czynniki rokownicze i predykcyjne w odniesieniu do immunoterapii. Najbardziej istotnymi elementami negatywnie wpływającymi na skuteczność immunoterapii są: gorszy stan sprawności, lokalizacja zmian wtórnych w wątrobie i mózgowiu, znaczne zaawansowanie zmian, nieprawidłowości w badaniach laboratoryjnych i brak korzyści klinicznej z wcześniej prowadzonego leczenia systemowego . Ponadto obserwuje się brak skuteczności immunoterapii wśród chorych z zaburzeniami molekularnymi (w szczególności w genach EGFR, ALK).
Słowa kluczowe: immunoterapiaczynniki prognostyczneczynniki predykcyjneniedrobnokomórkowy rak płuca
Referencje
- Manrique MA, Martínez JM, González JG, et al. Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience. Transl Lung Cancer Res. 2018; 7(3): 404–415.
- Juergens RA, Mariano C, Jolivet J, et al. Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort. Curr Oncol. 2018; 25(6): 384–392.
- Almazan M, Perez J, Pozo J, et al. A multicentre observational study of the effectivenes, safety and economic impact of nivolumab on non-small-cell lung cancer. International Journal of clinical Pharmacy. 2019; 41: 272–279.
- Schouten RD, Muller M, de Gooijer CJ, et al. Real life experience with nivolumab for the treatment of non-small cell lung carcinoma: Data from the expanded access program and routine clinical care in a tertiary cancer centre-The Netherlands Cancer Institute. Lung Cancer. 2018; 126: 210–216.
- Dudnik E, Moskovitz M, Daher S, et al. Effectiveness and safety of nivolumab in advanced non-small cel lung cancer. Lung cancer. 2018; 126: 217–223.
- Figueiredo A, Almeida MA, Almodovar MT, et al. Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in previously treated Non Small Cell Lung Cancer (NSCLC). Pulmonology. 2020; 26(1): 10–17.
- Ardizzoni A, Azevedo S, Rubio-Viqueira B, et al. Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer. J Immunother Cancer. 2021; 9(3).
- Velcheti V, Chandwani S, Chen X, et al. First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment. Immunotherapy. 2019; 11(10): 889–901.
- O'Connell JP, Kris MG, Gralla RJ, et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol. 1986; 4(11): 1604–1614.
- Vokes EE, Ready N, Felip E, et al. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol. 2018; 29(4): 959–965.
- Grossi F, Genova C, Crinò L, et al. Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer. Eur J Cancer. 2019; 123: 72–80.
- Kitadai R, Okuma Y, Hakozaki T, et al. The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases. J Cancer Res Clin Oncol. 2020; 146(3): 777–785.
- Rodríguez-Abreu D, Powell SF, Hochmair MJ, et al. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2020; 38(14): 1505–1517.
- Wang S, Hu C, Xie F, et al. Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer. Onco Targets Ther. 2020; 13: 667–683.
- Crinò L, Bronte G, Bidoli P, et al. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. Lung Cancer. 2019; 129: 35–40.
- Mansfield AS, Herbst RS, Castro G, et al. Outcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1–positive NSCLC with brain metastases: Pooled analysis of KEYNOTE-001, -010, -024, and -042. Ann Oncol. 2019; 30: v604–v606.
- Garassino MC, Gelibter AJ, Grossi F, et al. Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. J Thorac Oncol. 2018; 13(8): 1146–1155.
- Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17): 1627–1639.
- Fujimoto D, Yoshioka H, Kataoka Y, et al. Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study. Lung Cancer. 2018; 119: 14–20.
- Lai G, Alvarez J, Yeo J, et al. Randomised Phase 2 Study of Nivolumab (N) Versus Nivolumab and Ipilimumab (NI) Combination in EGFR Mutant NSCLC OA01.06 WCLC2020.
- Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019; 30(8): 1321–1328.
- Gandara D, Reck M, Moro-Sibilot D, et al. Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel. J Immunother Cancer. 2021; 9(3).
- Ruiz-Bañobre J, Areses-Manrique MC, Mosquera-Martínez J, et al. Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy. Transl Lung Cancer Res. 2019; 8(6): 1078–1085.
- Mezquita L, Auclin E, Ferrara R, et al. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018; 4(3): 351–357.
- Katsurada M, Nagano T, Tachihara M, et al. Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer. Anticancer Res. 2019; 39(2): 815–825.
- Hakozaki T, Hosomi Y, Kitadai R, et al. Efficacy of immune checkpoint inhibitor monotherapy for patients with massive non-small-cell lung cancer. J Cancer Res Clin Oncol. 2020; 146(11): 2957–2966.
